Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
22:48:59 EDT Thu 18 Apr 2024
Enter Symbol
or Name
USA
CA



Q:LXRX - LEXICON PHARMACEUTICALS INC - http://www.lexpharma.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
LXRX - Q1.41.62·1.712.51.63+0.010.63,714.95,7355,9241.67  1.73  1.623.789  0.9219:57:5608:0115 min RT 2¢

Recent Trades - Last 10 of 5924
Time ETExPriceChangeVolume
19:57:56Q1.650.0310
18:42:01Q1.640.02200
18:41:52Q1.640.02200
18:13:50Q1.650.0320
18:09:37Q1.64970.029715
18:06:31Q1.650.0310
17:15:29Q1.680.061,000
16:02:33Q1.630.019,684
16:02:27Q1.630.01860
16:01:36Q1.630.0188

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-18 08:01U:LXRXNews ReleaseLexicon Pharmaceuticals to Host 2024 Investor Day
2024-04-03 08:00U:LXRXNews ReleaseLexicon Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
2024-03-25 09:21U:LXRXNews ReleaseClinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of Cardiology 73rd Annual Scientific Session & Expo
2024-03-12 08:00U:LXRXNews ReleaseNew Post Hoc Analysis of inTandem3 Study Demonstrates Improvements In Glycemic Control With Sotagliflozin Treatment in Patients With Type 1 Diabetes and Chronic Kidney Disease
2024-03-11 07:15U:LXRXNews ReleaseLexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Provides Business Update
2024-03-11 07:05U:LXRXNews ReleaseLexicon Announces Oversubscribed $250 Million Private Placement of Equity Securities
2024-03-11 07:00U:LXRXNews ReleaseLexicon Preparing to Resubmit Sotagliflozin NDA for Type 1 Diabetes Following Feedback From FDA
2024-01-08 07:00U:LXRXNews ReleaseLexicon Pharmaceuticals Provides Business and Pipeline Update at 42nd Annual J.P. Morgan Healthcare Conference
2023-12-21 16:15U:LXRXNews ReleaseLexicon Pharmaceuticals To Participate In The 42nd Annual JPMorgan Healthcare Conference
2023-11-30 07:30U:LXRXNews ReleaseLexicon Enrolls First Patient in Phase 2b Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)
2023-11-22 07:30U:LXRXNews ReleaseLexicon Pharmaceuticals to Participate in the 35th Annual Piper Sandler Healthcare Conference and the 6th Annual Evercore ISI HealthCONx Conference
2023-11-12 14:10U:LXRXNews ReleaseINPEFA ‚ ® (sotagliflozin) Use Associated With Early Clinical Benefit in Heart Failure and Atherosclerotic Events in Analysis of Clinical Data
2023-11-10 16:01U:LXRXNews ReleaseLexicon Pharmaceuticals to Participate in the Jefferies London Healthcare Conference
2023-11-08 07:00U:LXRXNews ReleaseLexicon Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
2023-11-03 09:00U:LXRXNews ReleaseLexicon Pharmaceuticals to Host Third Quarter 2023 Financial Results Conference Call and Webcast on November 8, 2023
2023-11-02 09:00U:LXRXNews ReleaseData on Early Clinical Benefit for INPEFA ‚ ® (Sotagliflozin) Will Be Among Five Lexicon-Sponsored Presentations at the American Heart Association Scientific Sessions 2023
2023-11-01 09:00U:LXRXNews ReleaseINPEFA ‚ ® (Sotagliflozin) Receives Coverage From Express Scripts on Its Basic and High Performance Formularies for Commercially Insured Patients
2023-10-31 16:01U:LXRXNews ReleaseLexicon Strengthens Management Team With Two New Executives
2023-10-30 16:01U:LXRXNews ReleaseNew Data Relating to Sotagliflozin to be Presented at the American Society of Nephrology (ASN) Kidney Week 2023 Annual Meeting
2023-10-17 16:01U:LXRXNews ReleaseData From Two Studies Demonstrating Positive Financial Impact of INPEFA ‚ ® (Sotagliflozin) to be Presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023 National Meeting